Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

As previously reported, Guggenheim initiated coverage of Assembly Biosciences (ASMB) with a Buy rating and $31 price target. There remains a ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

A comprehensive study from Karolinska Institutet shows that people with fatty liver disease have almost twice the mortality ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

Google’s $32B Wiz acquisition raises questions on strategy, AI competition, and cloud dominance as investors react ...

Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences Inc. closed 8.11% short of its 52-week high of $119.96, which the company achieved on March 10th.

DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the evolving Metabolic Dysfunction-Associated Steatohepatitis (MASH) market ...

Gilead Sciences, Inc. today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference on Retroviruses ...

Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today ...